824 related articles for article (PubMed ID: 18268193)
1. Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis.
Chowdhury SA; Lin J; Sadiq SA
Arch Neurol; 2008 Feb; 65(2):232-5. PubMed ID: 18268193
[TBL] [Abstract][Full Text] [Related]
2. IL-15 is elevated in serum and cerebrospinal fluid of patients with multiple sclerosis.
Rentzos M; Cambouri C; Rombos A; Nikolaou C; Anagnostouli M; Tsoutsou A; Dimitrakopoulos A; Triantafyllou N; Vassilopoulos D
J Neurol Sci; 2006 Feb; 241(1-2):25-9. PubMed ID: 16316662
[TBL] [Abstract][Full Text] [Related]
3. Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients.
Lebrun C; Bensa C; Debouverie M; Wiertlevski S; Brassat D; de Seze J; Rumbach L; Pelletier J; Labauge P; Brochet B; Tourbah A; Clavelou P;
Arch Neurol; 2009 Jul; 66(7):841-6. PubMed ID: 19597085
[TBL] [Abstract][Full Text] [Related]
4. Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid.
Sarchielli P; Greco L; Floridi A; Floridi A; Gallai V
Arch Neurol; 2003 Aug; 60(8):1082-8. PubMed ID: 12925363
[TBL] [Abstract][Full Text] [Related]
5. Nitric oxide as an activity marker in multiple sclerosis.
Acar G; Idiman F; Idiman E; Kirkali G; Cakmakçi H; Ozakbaş S
J Neurol; 2003 May; 250(5):588-92. PubMed ID: 12736739
[TBL] [Abstract][Full Text] [Related]
6. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness.
Link H; Huang YM
J Neuroimmunol; 2006 Nov; 180(1-2):17-28. PubMed ID: 16945427
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor-2 levels are elevated in the cerebrospinal fluid of multiple sclerosis patients.
Sarchielli P; Di Filippo M; Ercolani MV; Chiasserini D; Mattioni A; Bonucci M; Tenaglia S; Eusebi P; Calabresi P
Neurosci Lett; 2008 Apr; 435(3):223-8. PubMed ID: 18353554
[TBL] [Abstract][Full Text] [Related]
8. Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis.
Kawajiri M; Mogi M; Osoegawa M; Matsuoka T; Tsukuda K; Kohara K; Horiuchi M; Miki T; Kira JI
Mult Scler; 2008 May; 14(4):557-60. PubMed ID: 18562510
[TBL] [Abstract][Full Text] [Related]
9. Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis.
Minneboo A; Barkhof F; Polman CH; Uitdehaag BM; Knol DL; Castelijns JA
Arch Neurol; 2004 Feb; 61(2):217-21. PubMed ID: 14967769
[TBL] [Abstract][Full Text] [Related]
10. Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis.
Rieckmann P; Altenhofen B; Riegel A; Baudewig J; Felgenhauer K
Ann Neurol; 1997 Mar; 41(3):326-33. PubMed ID: 9066353
[TBL] [Abstract][Full Text] [Related]
11. Correlation of clinical features and findings on cranial magnetic resonance imaging with urinary myelin basic protein-like material in patients with multiple sclerosis.
Whitaker JN; Williams PH; Layton BA; McFarland HF; Stone LA; Smith ME; Kachelhofer RD; Bradley EL; Burgard S; Zhao G
Ann Neurol; 1994 May; 35(5):577-85. PubMed ID: 7513981
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid levels of iodothyronines and nerve growth factor in patients with multiple sclerosis and neuromyelitis optica.
Jiang Y; Yang Y; Zhang B; Peng F; Bao J; Hu X
Neuro Endocrinol Lett; 2009 Mar; 30(1):85-90. PubMed ID: 19300400
[TBL] [Abstract][Full Text] [Related]
13. Increased levels of IL-23 and osteopontin in serum and cerebrospinal fluid of multiple sclerosis patients.
Wen SR; Liu GJ; Feng RN; Gong FC; Zhong H; Duan SR; Bi S
J Neuroimmunol; 2012 Mar; 244(1-2):94-6. PubMed ID: 22329905
[TBL] [Abstract][Full Text] [Related]
14. Calprotectin levels in the cerebrospinal fluid reflect disease activity in multiple sclerosis.
Berg-Hansen P; Vandvik B; Fagerhol M; Holmøy T
J Neuroimmunol; 2009 Nov; 216(1-2):98-102. PubMed ID: 19800696
[TBL] [Abstract][Full Text] [Related]
15. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis.
Sharief MK; Hentges R
N Engl J Med; 1991 Aug; 325(7):467-72. PubMed ID: 1852181
[TBL] [Abstract][Full Text] [Related]
16. MRI as an outcome in multiple sclerosis clinical trials.
Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis.
Terzi M; Birinci A; Cetinkaya E; Onar MK
Acta Neurol Scand; 2007 May; 115(5):325-30. PubMed ID: 17489943
[TBL] [Abstract][Full Text] [Related]
18. Assessment of outcome predictors in first-episode acute myelitis: a retrospective study of 53 cases.
Gajofatto A; Monaco S; Fiorini M; Zanusso G; Vedovello M; Rossi F; Turatti M; Benedetti MD
Arch Neurol; 2010 Jun; 67(6):724-30. PubMed ID: 20558391
[TBL] [Abstract][Full Text] [Related]
19. Interferon inhibitory activity in patients with multiple sclerosis.
Chadha K; Weinstock-Guttman B; Zivadinov R; Bhasi K; Muhitch J; Feichter J; Tamaño-Blanco M; Abdelrahman N; Ambrus J; Munschauer F; Ramanathan M
Arch Neurol; 2006 Nov; 63(11):1579-84. PubMed ID: 17101826
[TBL] [Abstract][Full Text] [Related]
20. Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity.
Szalardy L; Zadori D; Simu M; Bencsik K; Vecsei L; Klivenyi P
J Neurol Sci; 2013 Aug; 331(1-2):38-42. PubMed ID: 23706476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
